Clinical Trial Update: Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease

View source ↗

Summary

A completed postmarketing surveillance study of Berodual MDI in chronic obstructive pulmonary disease sponsored by Boehringer Ingelheim.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Berodual (ipratropium bromide + fenoterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Status: COMPLETED